Evotec AG reached its first milestone under a diabetes alliance with Sanofi, triggering a €3 million milestone payment for achieving preclinical proof of concept.

The collaboration between the two companies, signed in August 2015, aims to develop a therapy based on the functional beta cells derived from human stem cells, Evotec said in a news release.